T he G protein-coupled receptor kinases (GRKs) are a versatile family of kinases that play a critical role in G protein-coupled receptor homologous desensitization. GRKs phosphorylate specific serine and threonine residues in the cytoplasmic domains of the activated receptor, thereby promoting receptor-arrestin interaction and uncoupling of the receptor from its G protein (1) . The GRK family consists of seven members (GRK1-7) with differing patterns of expression. GRK1 and GRK7 are restricted to the visual system; GRK4 is found predominantly in the testis, whereas GRK2, GRK3, GRK5, and GRK6 are expressed in all mammalian cells (1, 2) . Although all GRKs have similar structural organization, they differ in their mechanisms of activation (2, 3) . GRK2 and GRK3 are pleckstrin homology do-main-containing proteins, which on receptor activation are recruited to the membrane by Gbg (4) (5) (6) . GRK4, GRK5, and GRK6, however, are membrane-associated proteins and are directly activated by the receptor-ligand complex (7) (8) (9) .
CXCR2 is a member of the CXC subfamily of chemokine receptors that interacts with CXCL1, CXCL2, CXCL3, CXCL5, CXCL7, and CXCL8 with high affinity (10, 11) . A hallmark of this subset of chemokines is the expression of a glutamic acid-leucinearginine (ELR) motif in their N terminus, which appears to be critical for receptor-mediated angiogenesis (12, 13) . Upon activation by ligand, CXCR2 becomes desensitized and downregulated (14) (15) (16) . Desensitization of CXCR2 occurs via two mechanisms: protein kinase C dependent or heterologous, and GRK-dependent or homologous (14, 17, 18) . We have recently shown that CXCR2 homologous desensitization occurs predominantly through phosphorylation of the receptor by GRK6 (19) . Murine neutrophils and RBL-2H3 cells deficient in GRK6 expression exhibited diminished CXCR2 phosphorylation, desensitization, and downregulation (19) . GRK6 2/2 mice also displayed greater neutrophil accumulation at the site of inflammation, enhanced angiogenesis, and faster wound closure relative to wild type (WT; GRK6 +/+ ) animals, indicating augmentation of CXCR2-dependent functions (19) . These results mirrored those previously obtained with the b-arrestin-2-deficient (barr2 2/2 ) mouse model and suggest that CXCR2 downmodulation via the GRK6/barr2 axis is critical in modulating inflammatory responses (20, 21) .
We have previously demonstrated that barr2 2/2 mice displayed faster tumor growth and metastasis relative to WT animals (21) . This effect was shown to be mediated via increased CXCR2mediated NF-kB activation (21) . Because GRK-mediated phosphorylation is critical for barr2 association with the receptor, we hypothesized that GRK6 inhibition could also promote CXCR2mediated tumor progression and metastasis. To test this hypothesis, we have used murine models of heterotopic Lewis lung cancer (LLC) and tail vein lung metastasis in GRK6 2/2 mice, GRK6 2/2 /barr2 2/2 double-knockout, and control littermates. The data in this study indicated that GRK6 depletion promoted angiogenesis, tumor development, and lung metastasis. These effects appear to be mediated through increased activation of the receptor leading to greater PMN accumulation and protease release in the tumor microenvironment, thereby promoting angiogenesis and tumor metastasis. Interestingly, GRK6 2/2 /barr2 2/2 animals showed greater tumor growth than that of GRK6 2/2 or barr2 2/2 . Taken together, the data indicate that CXCR2 couples to different mechanisms to promote angiogenesis and tumor development.
Materials and Methods

Materials
Lewis Lung carcinoma cell line (CRL-1642) was purchased from American Type Culture Collection. Anti-CD3, CD4, CD8a, CD45, NK1.1, and Ly6 were purchased from BD Pharmingen. Anti-CXCR2, keratinocyte-derived chemokine (CXCL1/KC), CXCL2/MIP-2, vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2), and MMP-9 Abs; recombinant murine CXCL1/KC, CXCL2/MIP-2, CXCL12/SDF1, VEGF, MMP-2, and MMP-9 proteins; MMP-2 and MMP-9 ELISA kits; CXCR2 inhibitor SB250002; and mouse chemokine array kits were purchased from R&D Systems. Goat anti-mCXCR2 antiserum was kindly provided by Dr. Robert M. Strieter (School of Medicine, University of Virginia, Charlottesville, VA). Monoclonal anti-b-actin and anti-factor VIII-related Ag Abs, 3,39,5,59-tetramethylbenzidine, ExtrAvidin-peroxidase, DNAse, and collagenase were purchased from Sigma Life Sciences. Microtiter plates and Bouin's fixative were purchased from VWR International. Gelatinprecast Ready Gel Zymogram Gels were obtained from Bio-Rad Laboratories. Novex Zymogram Developing Buffer was obtained from Invitrogen (Life Technologies). Monoclonal anti-phospho-NF-kB-p65 (Ser 536 ) and polyclonal anti-p65-NF-kB Abs were purchased from Cell Signaling Technology. All the other reagents were obtained from commercial sources.
Animals
All experiments were approved by and conformed to the guidelines of the Animal Care and Use Committee of North Carolina Central University (Durham, NC). GRK6 2/2 and barr2 2/2 mice (C57BL/6 background) were kindly provided by Dr. Robert J. Lefkowitz (Duke University Medical Center, Durham, NC). Male and female mice were evaluated, and control mice were age-and sex-matched littermates. All mice were genotyped at 21 d old; DNA samples were prepared from the tail tips with Extract-N-Amp tissue PCR kit from Sigma and subjected to triplex PCR as described previously (21, 22) . The GRK6 2/2 /barr2 2/2 double-knockout mouse model was generated by backcrossing GRK6 2/2 and barr2 2/2 animals. Double-knockout animals were confirmed by RT-PCR.
Heterotopic Lewis lung carcinoma model
LLC was a spontaneously occurring lung cancer in C57BL/6 mice. The CRL-1642 was routinely maintained in DMEM supplemented with 10% heat-inactivated FBS, 1.5 g/l sodium bicarbonate, 4 mM/l glutamine, 100 mg/ml streptomycin, and 100 IU/ml penicillin. GRK6 +/+ and GRK6 2/2 mice (6-8 wk, n = 14) were injected s.c. with LLC cells (5 3 10 5 cells in 100 ml). After each week, mice were euthanized by CO 2 asphyxiation; tumors were dissected from mice and measured with a Thorpe caliper (VWR). Tumor volume was calculated using the formula: Volume = (d 1 3 d 2 3 d 3 ) 3 0.5236, where d n represents the three orthogonal diameter measurements (21, 23) . Tumor and tissue specimens were either fixed in buffered formalin or processed for ELISA or FACS analysis.
Tail vein metastasis model
The LLC cells (3 3 10 5 viable cells per 100 ml) were injected via the tail vein of GRK6 +/+ and GRK6 2/2 mice (6-8 wk, n = 8). The mice were observed daily for any sign of respiratory distress and were euthanized by CO 2 after 4 wk. The lungs were removed and inflated with Bouin's fixative. The number of metastatic nodules on the lungs was counted with the aid of a dissecting microscope (21, 24) . For survival experiments, GRK6 +/+ and GRK6 2/2 mice (6-8 wk, n = 14) were injected as described earlier and observed daily for mortality. The experiment was terminated when all the mice died of either group.
FACS analysis of single-cell isolates from heterotopic LLC tumors
Tumors were isolated from mice (n = 6), minced with scissors to fine slurry, and incubated in digestion buffer (RPMI 1640, 5% FBS, 1 mg/ml collagenase and 30 mg/ml DNAse) at 37˚C for 45 min. Cells were washed, and cell counts and viability were determined using trypan blue exclusion on a hemocytometer. Cells (2 3 10 6 ) were resuspended in FACS analysis buffer and stained with PE-conjugated anti-mouse CD3, CD4, CD45, CD8a, NK1.1, Ly6, or factor VIII-related Ag Abs. Cells were also stained with rat anti-mouse CXCR2 and goat anti-rat PE-conjugated secondary Abs (21, 23) . Stained cells were analyzed on a FACScan Flow Cytometer using Cell Quest software (BD Biosciences). CXCL1/KC, CXCL2/MIP-2, CXCL12/SDF-1, VEGF, and MMP levels in tumors Heterotopic LLC tumors (n = 10) were harvested 4 wk postinoculation. One gram of dissected tumors was homogenized in 10 ml PBS. The quantity of murine CXCL1/KC, CXCL2/MIP-2, CXCL12/SDF-1, VEGF, MMP-2, and MMP-9 present in tissue homogenates was determined by specific ELISA, using a modification of the double-ligand method, as previously described (21, 23) . In brief, flat-bottom 96-well microtiter plates were coated with 100 ml/well of specific polyclonal anti-mouse CXCL1/KC, CXCL2/MIP-2, CXCL12/SDF-1, VEGF, MMP-2, and MMP-9 (1 mg/ml in coating buffer, pH 9.5) for 24 h at 4˚C and then washed three times with PBS, pH 7.5, plus 0.05% Tween 20 (wash buffer). Plates were blocked with 1% BSA in PBS for 90 min at 37˚C and then washed three times with wash buffer. A total of 100 ml supernatant from each homogenate was added in plates and then incubated at 37˚C for 90 min. Plates were washed three times; 100 ml biotinylated polyclonal anti-murine CXCL1/KC, CXCL2/MIP-2, CXCL12/SDF-1, VEGF, MMP-2, and MMP-9 (diluted in PBS, pH 7.5, 0.05% Tween 20) was added and then incubated at 37˚C for 45 min. Plates were washed three times; 100 ml ExtrAvidinperoxidase conjugate was added and then incubated for another 45 min at 37˚C. Plates were washed again, and 100 ml 3,39,5,59-tetramethylbenzidine chromogenic substrate was added. Plates were incubated at room temperature for 20-30 min, and the reactions were terminated by the addition of 100 ml/ well of 1 M H 2 SO 4 . Plates were read at 450 nm in an automated microplate reader (Perkin Elmer). The amount of mouse CXCL1/KC, CXCL2/MIP-2, CXCL12/SDF-1, VEGF, MMP-2, and MMP-9 present was determined by interpolation of a standard curve generated by known amounts of recombinant mouse CXCL1/KC, CXCL2/MIP-2, CXCL12/SDF-1, VEGF, MMP-2, and MMP-9, respectively.
MMP-9 activity
MMP-9 activity was determined as previously reported (25, 26) . In brief, tumor lysates (20 mg) or recombinant murine MMP-9 (5 ng), as positive control, were electrophoresed in 10% gelatin-precast Ready Gel Zymogram Gels (Bio-Rad Laboratories). The gels were washed twice in 2.5% Triton X-100 for 30 min and incubated overnight at 37˚C in Novex Zymogram Developing Buffer (Life Technologies, Carlsbad, CA). The gels were stained with 0.1% Coomassie Blue (R250) for 1 h and then destained in 5% acetic acid, 10% methanol. The activity of the MMP-9 relative to the control standard was determined by densitometric scanning of the gels with a UV transilluminator (BioDoc-It Imaging System, UVP, Upland, CA), and the images were analyzed by Adobe Photoshop (Adobe Systems, Mountain View, CA).
Treatments in vivo
GRK6 +/+ and GRK6 2/2 mice (6-8 wk) were injected s.c. with LLC cells as outlined earlier. Mice (n = 6) were injected i.p. with 500 ml of either neutralizing goat anti-mouse CXCR2, control (preimmune) serum, or no treatment every day for 4 wk. In subsequent experiments, LLC tumorbearing GRK6 +/+ and GRK6 2/2 mice (n = 5) were treated i.p. with the CXCR2 inhibitor SB225002 (5 mg/kg/day), control (PBS), or no treatment every day for 4 wk. Tumor volume was measured as described earlier.
Quantitation of microvessel density
Paraffin-embedded tumor tissues from GRK6 +/+ and GRK6 2/2 mice were processed for immunohistochemical localization of factor VIII-related Ag, as previously described (27) . In brief, tissue sections were dewaxed with xylene and rehydrated through graded series of alcohol. Tissue sections were treated with 0.10 M citric acid buffer in a heated pressure cooker for 10 min. Slides were blocked with normal goat serum and overlaid with 1:500 dilution of either control (rabbit) or anti-factor VIII-related Ag Ab for overnight at 4˚C. Slides were then rinsed and overlaid with secondary biotinylated goat anti-rabbit IgG (1:200) and incubated for 60 min. After washing with PBS, slides were overlaid with a 1:200 dilution of ExtrAvidin-peroxidase conjugate and incubated for 60 min. 393-Diaminobenzedine tetrahydrochloride was used for chromogenic localization of factor VIII-related Ag. After optimal color development, sections were washed with sterile water, counterstained with Mayer's hematoxylin, and dehydrated into the graded series of alcohol and mounted. Quantitation of microvessel density was performed using the previously described method with slight modifications (27) . Tumor specimens (n = 10) were scanned at low magnification (320) to identify vascular hotspots. Areas of greatest vessel density (six from each specimen) were then examined under higher magnification (3200) and counted with the help of grid eyepiece. Any distinct areas of positive staining for factor VIII-related Ag were counted as single vessels. Results were expressed as the number of microvessels per square millimeter.
Immunoblotting
For GRK6 expression analysis, LLC cells, zymosan-elicited PMNs (1 3 10 6 ) isolated from GRK6 +/+ and GRK6 2/2 mice, WT RBL-2H, and GRK6depleted RBL (RBL-GRK6 2/2 ), were lysed in radioimmune precipitation assay buffer and assayed for protein concentration. Twenty micrograms of proteins was resolved on 10% SDS-PAGE, transferred to nitrocellulose paper, probed with mouse monoclonal anti-GRK6 Ab, and detected with HRP-conjugated goat anti-mouse Ab and ECL. For NF-kB-p65 phosphorylation, zymosan-elicited PMNs (1 3 10 7 ) were treated with or without CXCL1/KC (1 mM) in PBS for 10 min at 37˚C. Then cells were washed, lysed, and immunoblotted with either anti-phospho-NF-kB-p65 or anti-NF-kB-p65 (21) .
Chemokine measurement in LLC cells
Chemokine levels were measured using the commercially available Mouse Chemokine Array (R&D Systems) according to the protocol supplied by the manufacturer. LLC cell lysates were prepared as described in the protocol and assayed for protein concentrations. Five hundred micrograms proteins were run on each array.
Statistical analyses
Results are expressed as mean 6 SEM. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). Differences between groups were determined using one-way ANOVA or Student t test (two-tailed), as appropriate. A p value ,0.05 was considered statistically significant.
Results
GRK6 depletion enhanced tumorigenesis and metastasis
To assess the role of GRK6 in tumor development, we injected 6-to 8-wk-old male GRK6 2/2 mice and control littermates (GRK6 +/+ ) heterotopically with LLC cells (5 3 10 5 ) under the dorsal skin. Tumor size was measured 4 wk after injection. As shown in Fig.  1A , tumor growth occurred faster in GRK6 2/2 mice as compared with GRK6 +/+ . Time course of tumor growth in both male ( Fig. 1B) and female (Fig. 1C ) mice showed a significant difference in tumor size relative to control animals. This result indicates that the actions of GRK6 oppose tumor growth in our s.c. tumor model.
We next determined the role of GRK6 deficiency in lung metastasis by measuring the number of metastatic nodules on the lungs. Colonization of the lung was significantly greater in GRK6 2/2 mice as compared with GRK6 +/+ ( Fig. 2A) . The number of metastatic tumor nodules was ∼6-fold higher in lungs from GRK6 2/2 mice relative to WT animals (Fig. 2B ). GRK6 deletion also caused a significant reduction in the median survival of GRK6 2/2 mice (∼22 d) relative to the GRK6 +/+ mice (∼40 d; Fig. 2C ).
We also measured the expression of GRK6 in LLC tumor cells, peritoneal neutrophils isolated from GRK6 2/2 and GRK6 +/+ mice, control RBL-2H3 cells (RBL-GRK6 +/+ ), and RBL-2H3 cells in which GRK6 was stably knocked down by short hairpin RNA (RBL-GRK6 2/2 ) (19) . As shown in Supplemental Fig. 1, GRK6 expression in LLC cells (lane 3) was similar to that of RBL-GRK6 +/+ cells (lane 4) and PMNs from GRK6 +/+ mice (lane 1). GRK6 expression was inhibited in PMNs from GRK6 2/2 (lane 2) mice, as well as RBL-GRK6 2/2 cells (lane 5). This result suggests that the effect of GRK6 inhibition in tumor growth is due to the host.
Effect of GRK6 depletion on chemokine, VEGF, and MMP expression
To determine the effect of GRK6 depletion on chemokine and proangiogenic factor expression, we measured the levels of CXCL1/KC, CXCL2/MIP-2, CXCL12/SDF-1, VEGF, MMP-2, and MMP-9 in the homogenate of the LLC tumors from GRK6 2/2 and control littermates. No significant changes in the levels of expression of CXCL1/KC (Fig. 3A) , CXCL2/MIP-2 ( Fig. 3B) , CXCL12/SDF-1 (Fig. 3C ), or VEGF (Fig. 3D) were observed. MMP-2 ( Fig. 3E ) and MMP-9 ( Fig. 3F ) expression levels, however, were significantly enhanced in tumors from GRK6 2/2 animals relative to GRK6 +/+ . The increased MMP-9 expression in GRK6 +/+ was further assessed by immunoblotting. As shown in Fig. 3G , tumor homogenate from GRK6 2/2 mice (lane 2) showed a marked increase in MMP-9 expression as compared with GRK6 +/+ (lane 1). MMP-9 activity in tumor homogenates was also examined using gelatin zymography. GRK6 2/2 mice (Fig.  3H, lane 2; Fig. 3I , closed bar) exhibited significantly greater MMP-9 activity relative to GRK6 +/+ (Fig. 3H, lane 3; Fig. 3I , open bar). Recombinant murine MMP-9 (Fig. 3H, lane 1) was used as positive control.
To further assess the role of GRK6 depletion in angiogenesis, we stained tumors with an Ab specific for factor VIII-related Ag for determination of microvessels density. Tumors from GRK6 2/2 mice (Fig. 4B, 4C , closed bar) showed a statistically significant increase in the number of microvessels density as compared with tumors from GRK6 +/+ mice (Fig. 4A, 4C , open bar).
Effect of GRK6 depletion on intratumor leukocyte infiltrations
We next analyze the intratumor leukocyte infiltration of cell isolates from LLC tumors of GRK6 2/2 and GRK6 +/+ mice. As shown in Table I , no significant difference was found in tumor infiltrating NK + , CD3 + , CD4 + , CD45 + , and CD8a + in GRK6 2/2 as compared with GRK6 +/+ mice. However, significant increases were observed in PMN, CXCR2, and factor VIII-related Ag-expressing cells in GRK6 2/2 relative to GRK6 +/+ mice (Table I) .
Inhibition of CXCR2 diminished the effect of GRK6 depletion in LLC tumor development
To assess the role of CXCR2 in GRK6-mediated tumor progression, we used a CXCR2 inhibitor SB225002 and a CXCR2neutralizing Ab to block the receptor in the heterotopic model. GRK6 2/2 mice treated with SB225002 showed a significant decrease (∼45%) in tumor size relative to nontreated animals ( Fig.  5A , closed bars). Treatment of GRK6 +/+ animals with SB225002, however, had no significant effect in tumor size ( Fig. 5A , open bars). Treatment of both GRK6 +/+ (Fig. 5B , open bars) and GRK6 2/2 (Fig. 5B , closed bars) mice with the anti-mouse CXCR2 Ab caused a significant decrease (∼85% for GRK6 +/+ and ∼73% for GRK6 2/2 ) in tumor size relative to untreated animals. The inhibitory effect of the murine CXCR2 Ab in tumor growth was greater than that of the pharmacological inhibitor SB225002 (∼85 versus 45%), relative to WT animals. This is likely due to the dose of SB225002 used in these experiments (5 mg/kg/d). Greater inhibitory effects in tumor volume were obtained with higher doses, 7.5 and 10 mg/kg/d (data not shown). However, because of the reduced survival rates (80-100% of the mice died between weeks 2 and 3) and the animals' aggressive behavior, we were limited to 5 mg/kg/d.
Are the effects of GRK6 and barr2 inhibition in LLC growth additive?
We have previously shown that deletion of barr2 promoted CXCR2mediated angiogenesis, tumor progression, and metastasis (19) . To determine whether the effects of barr2 and GRK6 deficiency are additive, we generated a double-knockout (GRK6 2/2 /barr2 2/2 ) animal model (Fig. 6A) . Six-to 8-wk-old male GRK6 2/2 /barr2 2/2 , barr2 2/2 , and WT mice were injected heterotopically with LLC cells (5 3 10 5 ) under the dorsal skin, and tumor size was measured 3 wk after injection. As shown in Fig. 6B and 6C, GRK6 2/2 /barr2 2/2 mice exhibited faster tumor growth relative to barr2 2/2 or WT animals.
We also examined the effect of CXCR2-neutralizing Ab in GRK6 2/2 /barr2 2/2 tumor growth. GRK6 2/2 /barr2 2/2 mice were injected heterotopically with LLC cells (2.5 3 10 5 ; the number of cells was reduced in half because of tumor size and concern by the animal facility) and treated daily with murine CXCR2 antiserum or goat serum (control). As shown in Fig. 7 , mCXCR2-treated animals exhibited a significant decrease (∼8%) in tumor growth as compared with control animals. This suggests that the effects of barr2 and GRK6 deletion in CXCR2-mediated LLC tumor growth are additive.
Discussion
CXCR2 binds the proangiogenic ELR + chemokines to mediate cellular responses including chemotaxis and angiogenesis. Elevated expression levels of CXCR2 were observed in several cancer cell types including melanoma, lung, gastric, and colon carcinoma cells, and were shown to be associated with enhanced angiogenesis (28) (29) (30) (31) (32) . Knockdown of CXCR2 in animal models of cancer was also shown to inhibit tumor growth and metastasis in several mouse models of cancers including melanoma, renal cell carcinoma, and LLC (23, 33, 34) . We have previously shown that deletion of barr2, a key regulator of CXCR2 functions, decreased receptor desensitization but promoted LLC progression and metastasis in mice (21) . Our recent studies using GRK6-deficient RBL-2H3 cells and mouse models of inflammation have shown that GRK6-mediated phosphorylation of CXCR2 plays an important role in receptor desensitization and downregulation, as well as receptor-induced angiogenesis and wound closure (19) . In this study, we investigated the role of GRK6 depletion in CXCR2mediated tumorigenesis. The results in this article clearly demonstrated that, as was the case for barr2 2/2 mice, deletion of GRK6 promoted CXCR2-mediated tumor progression and metastasis. First, heterotopically implanted LLC tumors in GRK6 2/2 mice showed a significant increase in tumor growth compared with WT mice (Fig. 1A-C) . Second, in the tail vein metastasis assay, the number of metastatic nodules significantly increased in the lung of GRK6 2/2 mice ( Fig. 2A, 2B ). Third, survival rate of GRK6 2/2 mice decreased very significantly relative to GRK6 +/+ (Fig. 2C) . Fourth, tumors from GRK6 2/2 mice showed significantly greater microvessels density as compared with WT animals (Fig. 4 ). And fifth, treatment of the mice with anti-CXCR2 Ab or the CXCR2-specific inhibitor, SB225002, abolished the effect of GRK6 depletion (Fig. 5 ).
Upregulation of ELR + chemokines in the tumor microenvironment is known to promote tumor angiogenesis (35, 36) . In barr2 2/2 animals, the increased tumor development and metastasis correlated with enhanced production of CXCL1/KC, CXCL2/MIP-2, and VEGF (21) . Surprisingly, tumors from GRK6 2/2 animals displayed levels of CXCL1/KC, CXCL2/MIP-2, and VEGF similar to those of WT GRK6 +/+ mice (Fig. 3A-D) . These results contrast with the barr2 2/2 LLC model and suggest that the increased tumor growth and metastasis caused by GRK6 inhibition likely occurs via a mechanism different from that of induction of proangiogenic chemokine production. Indeed, although barr2 2/2 mice displayed significant increase in NF-kB activity relative to barr2 +/+ (21) , CXCL1/KC-induced NF-kB p65 phosphorylation in peritoneal neutrophils from GRK6 2/2 animals was similar to that of control GRK6 +/+ (data not shown). Interestingly, both MMP-2 and MMP-9 were upregulated in GRK6 2/2 tumors relative to WT GRK6 +/+ (Fig. 3E-G) . Several studies have shown that degradation of the extracellular matrix by MMPs is critical for endothelial cell angiogenesis (37) (38) (39) . The CXCL8/ CXCR2 axis was also shown to mediate tumor angiogenesis and metastasis via upregulation of MMP-2 and MMP-9 (40, 41) . Peritoneal neutrophils and RBL-2H3 cells deficient in GRK6 exhibited increased CXCR2-mediated G protein activation and exocytosis (19) . Therefore, it is possible that the increase in tumor angiogenesis and metastasis observed in GRK6-deficient animals is due to increased production of MMPs mediated by the host CXCR2 ( Fig. 3E-G) . Supporting that contention is that Western blot analysis and gelatin zymography showed significant increase in MMP-9 expression and activity in tumor homogenate from GRK6 2/2 mice relative to GRK6 +/+ animals ( Fig. 3G-I) .
The infiltration of immune cells into the tumor microenvironment is a key component of the tumor immunity (42) . GRK6 2/2 depletion had no effect on T cell infiltration into the tumors but caused a significant increase in the level of PMNs (Table I) . These observations also contrast with the barr2 2/2 model of LLC, which displayed a significant decrease in T cell infiltration but no effect in PMN levels in the tumor microenvironment, relative to tumors from barr2 +/+ mice (21) . The role of PMNs in tumor infiltrates remains unclear. They have been associated with both better prognosis because of their phagocytic activities and poorer outcomes because of their abilities to release proangiogenic factors such as chemokines, VEGF, and MMPs (43, 44) . Interestingly, the increased levels of PMNs observed in GRK6 2/2 tumor infiltrates in this study correlated with enhanced expression of MMP-2 and MMP-9 (Fig. 3E, 3F ). Thus, the increased tumor growth and decreased survival rate of GRK6 2/2 animals compared with control GRK6 +/+ could be a consequence of PMNs increased activity resulting in greater secretion of proteases and tissue digestion, thereby promoting angiogenesis.
LLC cells express both GRK6 and CXCR2 (Supplemental Fig.  1 ) (23) . Mice deficient in CXCR2 showed decreased tumor progression and metastasis (23) . Thus, as was the case for the barr2 knockout model, the enhanced tumor growth and metastasis exhibited by GRK6 2/2 animals is likely due to increased CXCR2 activity of the host endothelial cells. Supporting that contention is that immunostaining of tumor sections with anti-factor VIIIrelated Ag (specific for endothelial cells) showed a significant increase in microvessel density in GRK6 2/2 mice relative to GRK6 +/+ mice (Fig. 4) . Keane et al. (23) have also shown that in LLC tumors, the cells expressing CXCR2 are predominantly the vascular endothelial cells.
Chemokine profiling of LLC cells using a mouse chemokine array revealed that these cells predominantly express CXCL1/KC (Supplemental Fig. 2 ). Whether LLC produced chemokines that play a role in the enhanced PMN infiltrations and/or increased tumor growth in GRK6 2/2 animals remains unclear. However, both GRK6 2/2 and GRK6 +/+ tumors showed similar levels of CXCL1/KC and CXCL2/MIP-2 expression (Fig. 3A, 3B ). Furthermore, mice deficient in CXCR2 or treated with a CXCR2 blocking Ab displayed decreased chemokine expression and tumor growth, but similar levels of PMN in the tumor infiltrates (23) . Raghuwanshi et al. (21) have also shown that tumors from barr2 2/2 animals displayed increased CXCL1/KC and CXCL2/ MIP-2, but similar level of PMNs in the tumor infiltrates. Taken together, these results further suggest that the effect of GRK6 deletion in tumor growth is due to increased CXCR2 activity in the host, but not the LLC cells. Because the effects of GRK6 and barr2 in CXCR2-induced tumor growth appeared to be mediated via distinct mechanisms, we hypothesized that deletion of the two molecules could have an additive effect. Indeed, the double-knockout GRK6 2/2 barr2 2/2 displayed tumor growth at a faster rate than those of the singleknockout animals (Fig. 6 ). The size of the GRK6 2/2 barr2 2/2 tumors at week 3 was similar to those of barr2 2/2 or GRK6 2/2 at week 4 (data not shown). These results further indicate that CXCR2 modulate LLC tumor development through different mechanisms. One could be through barr2-mediated regulation of NF-kB and expression of proangiogenic factors (21) , and another through activation of GRK6 and production of MMPs.
In summary, the data in this article demonstrate that GRK6 plays a feedback regulatory role in CXCR2-mediated tumor development, invasion, and metastasis. In contrast with barr2, these processes appear to be mediated through increased activity of CXCR2 resulting in greater production of matrix MMPs and enhanced angiogenesis. Both CXCR1 and CXCR2 were shown to mediate angiogenesis via increased MMP production (40, 41) . Thus, an unanswered question is whether GRK6 deletion would also enhance CXCR1-mediated tumor growth? To date, conflicting reports exist concerning the expression and function of a murine homolog of CXCR1 (45) (46) (47) . Fan et al. (47) have recently identified a possible mouse CXCR1 that binds CXCL6/GCP-2 and CXCL8/IL-8 with high affinity. Studies in RBL-2H3 cell stably expressing CXCR1, however, have shown that the receptor couples predominantly to GRK2 to mediate and regulate cellular responses (19) . Therefore, it is unlikely that deletion of GRK6 would have a significant effect in CXCR1-mediated tumor growth and metastasis.
